Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Oncoproteínas/proteínas virales recombinantes para kits de diagnóstico de cánceres relacionados con el virus del papiloma humano


Oferta Tecnológica
Una spin-off italiana especializada en actividades innovadoras de investigación en los campos de biomateriales, biotecnología, medicina regenerativa, salud y bienestar ha desarrollado y patentado un nuevo método para producir proteínas virales recombinantes (por ejemplo, la oncoproteína E6) útiles para desarrollar nuevos kits de diagnóstico temprano de cánceres relacionados con el virus del papiloma humano (HPV). Las principales ventajas de estos kits son la rentabilidad, facilidad de uso y detección fiable. Como aspecto innovador cabe destacar el uso de polímeros biocompatibles aprobados por la FDA para inmovilizar las oncoproteínas producidas por electrospinning y otras técnicas de fabricación. La empresa busca socios con el fin de establecer acuerdos de I+D o joint venture para continuar con el desarrollo de la tecnología.


Recombinant viral proteins/oncoproteins for diagnostic kits for human papillomavirus related cancers
An italian spin off has developed an innovative patented method to produce recombinant viral proteins (for example E6 oncoprotein) useful to develop new early diagnostic kits for human papillomavirus (HPV) - related cancers. One of the main advantages of such kits is a low cost, user-friendly, reliable screening.
The SME is looking for R-Y-D agreement or joint venture to further develop this technology on the market.
The Italian SME is involved in innovative research activities in the fields of biomaterials, biotechnology, with an emphasis on regenerative medicine, health, and well being. Several collaborations with research laboratories and industries across Europe are ongoing.
A new patented procedure is offered from this SME to obtain a stable, unmutated E6 protein (from HPV-16, -18, -11) in native conditions.
The "high-risk human papillomaviruses" (HR-HPVs) are the etiologic agents of cervical cancer but are also associated to anal and oropharyngeal cancers. The over-expression of E6 and E7 oncoproteins is a necessary step toward HPV disease progression and cancer. Hence their direct/indirect detection would offer new opportunities to develop tests to distinguish self-resolving HPV infections from infections that are progressing to cancer.
Very recently, the HPV16 E6 protein was identified as an early biomarker for HPV-driven cancers, since E6 seropositivity was found to be present as early as 10 years before the diagnosis of oropharyngeal cancers.
Yet, the HPV E6 protein is extremely difficult to obtain as soluble when expressed in a recombinant form.
The E6 and E7 oncoproteins, together with other recombinant HPV proteins produced in our facilities by this method can be used for the development of new diagnostic kits as well as to get highly specific antibodies that are still lacking in the market and highly desirable.
The team is looking for partners in H2020 proposal, private financing or also through contractual joint venture (JVC) to bring a simple, rapid, reliable, portable, low-cost diagnostic kit for early detection of HPV-related cancers.
Advantages and Innovations:
Innovative aspects are:
- reliable production and storage of E6 oncoprotein from several HPV types,
- usage of biocompatible, FDA (Food and Drug Administration) approved polymers to immobilize the oncoproteins produced by electrospinning and other biofabrication techniques.

Advantages compared with other existing products are:
- no other kits available (commercially to our knowledge) based on detection of antibodies of E6,
- very stable protein for long shelf life,
- appealing to worldwide market.

The E6 and E7 oncoproteins, together with other recombinant HPV proteins produced in our SME, can be used for the development of new diagnostics, as well as for obtaining highly specific antibodies that are still lacking in the market.
Stage of Development:
Under development/lab tested
Patents granted
CommeR Statunts Regarding IPR Status:
Italian patent licensed exclusively to the SME

Partner sought

Type and Role of Partner Sought:
The research group is looking for partners with the following roles:
- R-Y-D partner with specific focus area in immunology, toxicology, good manufacturing practices production,
- private financing (also in equity) to boost development, commercialization, distribution,
- R-Y-D partner capable to certify our products for in-vitro screening


Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
02007020 Biobased materials
06001005 Diagnósticos, diagnosis
06001002 Investigaciones clínicas, ensayos
02007024 Nanomaterials
06001013 Tecnología médica / ingeniería biomédica